A phase II study of gemcitabine in patients with relapsed or refractory low-grade non-Hodgkin lymphoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 2, 2005, Pages 165-168

  Larson, Bradley J G ^a   Waples, John M ^a   Pusateri, Annette ^a   Mendenhall, Nancy P ^a   Lynch Jr , James W ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Division of Hematology/Oncology   (United States)

Author keywords

Gemcitabine; Low grade non Hodgkin lymphoma; Phase II

Indexed keywords

CLADRIBINE; CYTARABINE; CYTOTOXIC AGENT; FLUDARABINE; GEMCITABINE; NUCLEOSIDE ANALOG;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; ATAXIA; BACTEREMIA; BLOOD TOXICITY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GRAM NEGATIVE INFECTION; HISTOLOGY; HUMAN; HYPOTENSION; INFECTION; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROSPECTIVE STUDY; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; HUMANS; LYMPHOMA, LOW-GRADE; MALE; MIDDLE AGED;

EID: 17044366130     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000143015.66143.22     Document Type: Article

References (10)

1. American Cancer Society. Cancer Facts and Figures 2004.
2. Hainesworth JD, Burris HA, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000;95:3052-3056.
3. Redman JR, Cabanillas F, Velasquez WS, et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol. 1992;10:790-794.
4. Klasa R, Meyer R, Shustik C, et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J Clin Oncol. 2002;20:4649-4654.
5. Csoka K, Liliemark J, Larsson R, et al. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells with hematologic or solid tumors. Semin Oncol. 1995;22:47-53.
6. Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol. 2000;18:2615-2619.
7. Fossa A, Santoro A, Hiddemann W, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3786-3792.
8. Dumontet C, Morschhauser F, Solal-Celigny P, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol. 2001;113:772-778.
9. Jajeh A, Hadad L, Zalzaleh G, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma. Blood. 2002;100:abstract 4735.
10. Younes A, Pro B, Goy A, et al. Gemcitabine plus rituximab therapy of patients with relapsed and refractory classical Hodgkin disease: depletion of benign B-cells from HD microenvironment by rituximab may enhance the activity of gemcitabine. Blood. 2003;102:abstract 1500.